Home > Insider Trading > Filing (0000919574-24-002558)

Filing Details

Accession Number:: 0000919574-24-002558
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-04-15 19:21:50
Reporting Period:: 2024-04-11

Accepted Time:: 2024-04-15 19:21:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1642380	Oncocyte Corp	OCX	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1278386	Broadwood Partners, L.p.	C/O Broadwood Capital Inc. 142 West 57Th Street, 11Th Floor New York NY 10019	No	No	Yes	No
1278387	Broadwood Capital Inc	142 West 57Th Street, 11Th Floor New York NY 10019	No	No	Yes	No
1278388	C Neal Bradsher	C/O Broadwood Capital Inc. 142 West 57Th Street, 11Th Floor New York NY 10019	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, No Par Value	Acquisiton	2024-04-11	2,420,000	$2.92	4,929,066	No	4	P	Direct
Common Stock, No Par Value	Acquisiton	2024-04-11	0	$0.00	4,929,066	No	4	P	Indirect	Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2024-04-15	2,941	$0.00	107,488	$30.60
Common Stock	Series A Convertible Preferred Stock	Disposition	2024-04-15	0	$0.00	107,488	$30.60

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	J	Direct
0			No	4	J	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, No Par Value	157	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Warrant to Purchase Common Stock	$30.60		2027-04-19	150,093	150,093	Direct
Common Stock	Warrant to Purchase Common Stock	$30.60		2027-04-19	150,093	150,093	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2027-04-19	150,093	150,093	Direct
2027-04-19	150,093	150,093	Indirect

Footnotes

The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
These securities are directly owned by Neal C. Bradsher
On April 11, 2024, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the "Issuer") pursuant to which Broadwood Partners agreed to acquire 2,420,000 shares of the Issuer's Common Stock, no par value (the "Common Shares"), from the Issuer in a private placement for a total purchase price of $7,057,688, or $2.9164 per Common Share.
On April 15, 2024, the Issuer mandatorily redeemed all of the 2,941.1765 shares of Series A Convertible Preferred Stock of the Issuer (the "Series A Shares") previously owned by Broadwood Partners in accordance with the terms of the Securities Purchase Agreement with the Issuer to which Broadwood Partners acquired the Series A Shares (the "Series A Purchase Agreement"). Pursuant to the Series A Purchase Agreement, Broadwood Partners received $3,289,144.18, or $1,118.30902 per Series A Share, in redemption proceeds attributable to the Issuer's mandatory redemption. The Series A Shares were convertible at the time of the Issuer's mandatory redemption
These warrants are currently exercisable.